Cell-therapeutics R&D strategy
Define the indication, target population, modality, product hypothesis, mechanism, differentiation, evidence gaps, and stage-gated development plan.
Services
Development services for cell-therapeutics programs
From research framing and product control to U.S. IND readiness, technical training, and practical quality systems.
U.S. regulatory & IND planning
Map the likely regulatory pathway, prepare focused FDA meeting questions, structure the IND workstreams, and maintain an evidence-to-claim traceability record.
CMC & analytical development
Develop product definition, critical quality attributes, manufacturing controls, release tests, potency strategy, stability, and comparability planning.
Nonclinical & translational planning
Design a risk-based program spanning pharmacology, toxicology, biodistribution, persistence, immunogenicity, tumorigenicity when relevant, and route-specific safety.
Clinical development support
Support protocol concepts, dose and route rationale, safety monitoring, endpoint selection, vendor evaluation, operational readiness, and document review.
GMP facility & quality readiness
Plan stage-appropriate cleanroom, equipment, qualification, SOP, training, deviation, change-control, supplier, and documentation systems.
Research materials & assay support
Scope research-use cell materials, characterization, assay development, reference controls, and documentation against a defined study purpose.
Extracellular-vesicle research workflows
Support research-stage isolation, characterization, assay selection, reproducibility, and scale considerations. No human-use or approved-therapy claim is implied.
Technical training
Build focused training around cell culture, aseptic processing, analytical methods, documentation, QC, and the client’s actual procedures.
Program governance & vendor review
Clarify decisions, owners, milestones, dependencies, quality agreements, CDMO/CRO criteria, risks, and escalation paths.